Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate March 1, 2023
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate December 22, 2022
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate August 24, 2022
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer June 23, 2022